skip navigation

Skip Nav

Clinical Guidelines Portal

skip navigation

Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States

Appendix C: Acronyms

(Last updated:3/28/2014; last reviewed:3/28/2014)

Acronym/Abbreviation Full Name
3TC lamivudine
ABC abacavir
ACOG American College of Obstetricians and Gynecologists
ALT alanine aminotransferase
anti-HBc anti-hepatitis B core antibody
anti-HBS hepatitis B surface antibody
AP antepartum
APR Antiretroviral Pregnancy Registry
ART antiretroviral therapy
ARV antiretroviral
AST aspartate aminotransferase
ATV atazanavir
ATV/r ritonavir-boosted atazanavir
AUC area under the curve
AZT zidovudine
BID twice daily
BMI body mass index
cART combination antiretroviral therapy
CBC complete blood count
CD4 CD4 T lymphocyte 
CDC  Centers for Disease Control and Prevention
CI confidence interval
Cmax  maximum plasma concentration
Cmin minimum plasma concentration
CNS  central nervous system
COBI  cobicistat 
CVS  chorionic villus sampling 
CYP  cytochrome P
CYP3A4  cytochrome P450 3A4 
d4T  stavudine 
ddI   didanosine 
DMPA  depot medroxyprogesterone acetate 
DRV darunavir 
DRV/r  ritonavir-boosted darunavir 
DTG  dolutegravir 
DSMB  Data and Safety Monitoring Board
EC  enteric coated
ECG  electrocardiogram 
EFV efavirenz 
EMS ethyl methane sulfonate 
EPPICC  The European Pregnancy and Paediatric HIV Cohort Collaboration 
ETR  etravirine 
EVG  elvitegravir 
FDA  Food and Drug Administration 
FDC  fixed drug combination 
FPV  fosamprenavir 
FPV/r  ritonavir-boosted fosamprenavir 
FTC  emtricitabine 
gp  glycoprotein 
HAV  hepatitis A virus 
HBIG  hepatitis B immune globulin 
HBsAg hepatitis B surface antigen
HBV  hepatitis B virus 
HCV  hepatitis C virus 
HELLP  hemolysis, elevated liver enzymes, and low platelets 
HGC  hard gel capsule 
HR  hazard ratio 
HRSA  Health Resources and Services Administration
HSR  hypersensitivity reaction
IC50  inhibitory concentration 50% 
IDV
indinavir
IDV/r  ritonavir-boosted indinavir 
IGF
insulin-like growth factor 
IP 
intrapartum 
IQR 
interquartile range 
IRIS 
immune reconstitution inflammatory syndrome 
IUD 
intrauterine device 
IV 
intravenous/intravenously 
LPV 
lopinavir 
LPV/r 
ritonavir-boosted lopinavir 
MAC 
Mycobacterium avium complex 
MACDP 
Metropolitan Atlanta Congenital Defects Program 
MIRIAD 
Mother-Infant Rapid Intervention at Delivery (study) 
mtDNA   mitochondrial DNA
MVC  maraviroc 
NFV   nelfinavir 
NIH  National Institutes of Health 
NNRTI   non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor 
NRTI nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor
NtRTI  nucleotide analogue reverse transcriptase inhibitor 
NVP   nevirapine 
OC   oral contraceptive 
OI   opportunistic infection 
OR   odds ratio 
PACTG   Pediatric AIDS Clinical Trials Group  
The Panel   The Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission 
PCP   Pneumocystis jirovecii pneumonia 
PCR  polymerase chain reaction 
PI   protease inhibitor 
PK pharmacokinetic 
PO   orally 
PP  postpartum 
PPI  proton pump inhibitor 
PrEP   pre-exposure prophylaxis 
PTD   preterm delivery 
RAL   raltegravir 
RDS   respiratory distress syndrome 
RPV  rilpivirine
RR   relative risk 
RTV 
ritonavir 
sd 
single dose
SQ 
subcutaneous
SQV 
saquinavir 
SQV/r 
ritonavir-boosted saquinavir 
STD 
sexually transmitted disease
T20  enfuvirtide
TDF 
tenofovir disoproxil fumarate 
TDM  therapeutic drug monitoring
TID 
three times daily
TPV 
tipranavir 
TPV/r 
ritonavir-boosted tipranavir 
UGT 
uridine diphosphate glucuronosyltransferase 
WHO 
World Health Organization
WITS  Women and Infants Transmission Study 
ZDV
zidovudine